{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T01:28:04Z","timestamp":1789003684104,"version":"build-2803163510"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2019,3,6]],"date-time":"2019-03-06T00:00:00Z","timestamp":1551830400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,3,6]],"date-time":"2019-03-06T00:00:00Z","timestamp":1551830400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["1R01-HD076676-01A1"],"award-info":[{"award-number":["1R01-HD076676-01A1"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2019,7,1]]},"DOI":"10.1007\/s40262-018-00733-1","type":"journal-article","created":{"date-parts":[[2019,3,6]],"date-time":"2019-03-06T06:20:49Z","timestamp":1551853249000},"page":"887-898","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Physiologically Based Pharmacokinetic Modeling for Trimethoprim and Sulfamethoxazole in Children"],"prefix":"10.1007","volume":"58","author":[{"given":"Elizabeth J.","family":"Thompson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huali","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anil","family":"Maharaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea N.","family":"Edginton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Balevic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjan","family":"Cobbaert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony P.","family":"Cunningham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph P.","family":"Hornik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Cohen-Wolkowiez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,3,6]]},"reference":[{"key":"733_CR1","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.clinthera.2007.02.018","volume":"29","author":"R Alonso Campero","year":"2007","unstructured":"Alonso Campero R, Bernardo Escudero R, Del Cisne Valle Alvarez D, Gonz\u00e1lez de la Parra M, Namur Montalvo S, Burke Fraga V, et al. Bioequivalence of two commercial preparations of trimethoprim\/sulfamethoxazole: a randomized, single-dose, single-blind, crossover trial. Clin Ther. 2007;29:326\u201333.","journal-title":"Clin Ther."},{"key":"733_CR2","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.ejpb.2004.03.001","volume":"58","author":"M Lindenberg","year":"2004","unstructured":"Lindenberg M, Kopp S, Dressman JB. Classification of orally administered drugs on the World Health Organization Model list of Essential Medicines according to the biopharmaceutics classification system. Eur J Pharm Biopharm. 2004;58:265\u201378.","journal-title":"Eur J Pharm Biopharm."},{"key":"733_CR3","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1208\/s12248-009-9144-x","volume":"11","author":"A Dahan","year":"2009","unstructured":"Dahan A, Miller JM, Amidon GL. Prediction of solubility and permeability class membership: provisional BCS classification of the world\u2019s top oral drugs. AAPS J. 2009;11:740\u20136.","journal-title":"AAPS J."},{"key":"733_CR4","doi-asserted-by":"crossref","first-page":"Supp 32","DOI":"10.1136\/pgmj.45.519.32","volume":"45","author":"DE Schwartz","year":"1969","unstructured":"Schwartz DE, Zeigler WH. Assay and pharmacokinetics of trimethoprim in man and animals. Postgrad Med J. 1969;45:Supp 32\u20137.","journal-title":"Postgrad Med J."},{"key":"733_CR5","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1097\/01.ju.0000130653.74548.d6","volume":"172","author":"E Karpman","year":"2004","unstructured":"Karpman E, Kurzrock EA. Adverse reactions of nitrofurantoin, trimethoprim and sulfamethoxazole in children. J Urol. 2004;172:448\u201353.","journal-title":"J Urol."},{"key":"733_CR6","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1128\/AAC.35.9.1884","volume":"35","author":"RC Stevens","year":"1991","unstructured":"Stevens RC, Laizure SC, Williams CL, Stein DS. Pharmacokinetics and adverse effects of 20-mg\/kg\/day trimethoprim and 100-mg\/kg\/day sulfamethoxazole in healthy adult subjects. Antimicrob Agents Chemother. 1991;35:1884\u201390.","journal-title":"Antimicrob Agents Chemother."},{"key":"733_CR7","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1111\/j.1365-2125.1985.tb05114.x","volume":"20","author":"O Varoquaux","year":"1985","unstructured":"Varoquaux O, Lajoie D, Gobert C, Cordonnier P, Ducreuzet C, Pays M, et al. Pharmacokinetics of the trimethoprim-sulfamethoxazole combination in the elderly. Br J Clin Phamarcol. 1985;20:575\u201381.","journal-title":"Br J Clin Phamarcol."},{"key":"733_CR8","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1128\/AAC.39.1.28","volume":"39","author":"TW Chin","year":"1995","unstructured":"Chin TW, Vandenbroucke A, Fong IW. Pharmacokinetics of trimethoprim-sulfamethoxazole in critically ill and non-critically ill AIDS patients. Antimicrob Agents Chemother. 1995;39:28\u201333.","journal-title":"Antimicrob Agents Chemother."},{"key":"733_CR9","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1177\/089686088900900110","volume":"9","author":"SE Walker","year":"1989","unstructured":"Walker SE, Paton TW, Churchill DN, Ojo B, Manuel MA, Wright N. Trimethoprim-sulfamethoxazole pharmacokinetics during continuous ambulatory peritoneal dialysis (CAPD). Perit Dial Int. 1989;9:51\u20135.","journal-title":"Perit Dial Int."},{"key":"733_CR10","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1128\/AAC.37.3.448","volume":"37","author":"RC Stevens","year":"1993","unstructured":"Stevens RC, Laizure SC, Sanders PL, Stein DS. Multiple-dose pharmacokinetics of 12 milligrams of trimethoprim and 60 milligrams of sulfamethoxazole per kilogram of body weight per day in healthy volunteers. Antimicrob Agents Chemother. 1993;37:448\u201352.","journal-title":"Antimicrob Agents Chemother."},{"key":"733_CR11","unstructured":"BACTRIM\u2014sulfamethoxazole and trimethoprim tablet package insert. Philadelphia: AR Scientific, Inc; 2013."},{"key":"733_CR12","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1093\/jac\/22.6.873","volume":"22","author":"V Yeldandi","year":"1988","unstructured":"Yeldandi V, Strodtman R, Lentino J. In-vitro and in-vivo studies of trimethoprim-sulphamethoxazole against multiple resistant Staphylococcus aureus. J Antimicrob Chemother. 1988;22:873\u201380.","journal-title":"J Antimicrob Chemother."},{"key":"733_CR13","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1592\/phco.22.12.983.33599","volume":"22","author":"S Close","year":"2002","unstructured":"Close S, McBurney CR, Garvin CG, Chen DC, Martin SJ. Trimethoprim-sulfamethoxazole activity and pharmacodynamics against glycopeptide-intermediate Staphylococcus aureus. Pharmacotherapy. 2002;22:983\u20139.","journal-title":"Pharmacotherapy."},{"key":"733_CR14","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.1128\/AAC.05360-11","volume":"56","author":"M Martinez","year":"2012","unstructured":"Martinez M, Papich M, Drusano G. Dosing regimen matters: the importance of early intervention and rapid attainment of the pharmacokinetic\/pharmacodynamic target. Antimicrob Agents Chemother. 2012;56:2795\u2013805.","journal-title":"Antimicrob Agents Chemother."},{"key":"733_CR15","first-page":"73","volume":"112","author":"CM Wilfert","year":"1975","unstructured":"Wilfert CM, Gutman LT. Pharmacokinetics of trimethoprim-sulfamethoxazole in children. Can Med Assoc J. 1975;112:73\u20136.","journal-title":"Can Med Assoc J."},{"key":"733_CR16","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1136\/adc.60.1.29","volume":"60","author":"GW Rylance","year":"1985","unstructured":"Rylance GW, George RH, Healing DE, Roberts DG. Single dose pharmacokinetics of trimethoprim. Arch Dis Child. 1985;60:29\u201333.","journal-title":"Arch Dis Child."},{"key":"733_CR17","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1586\/ecp.11.43","volume":"4","author":"MM Laughon","year":"2011","unstructured":"Laughon MM, Benjamin DK Jr, Capparelli EV, Kearns GL, Berezny K, Paul IM, et al. Innovative clinical trial design for pediatric therapeutics. Expert Rev Clin Pharmacol. 2011;4:643\u201352.","journal-title":"Expert Rev Clin Pharmacol."},{"key":"733_CR18","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1053\/j.semperi.2015.08.007","volume":"39","author":"K Zimmerman","year":"2015","unstructured":"Zimmerman K, Gonzalez D, Swamy GK, Cohen-Wolkowiez M. Pharmacologic studies in vulnerable populations: Using the pediatric experience. Semin Perinatol. 2015;39:532\u20136.","journal-title":"Semin Perinatol."},{"key":"733_CR19","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1586\/ecp.09.40","volume":"2","author":"SE Kern","year":"2009","unstructured":"Kern SE. Challenges in conducting clinical trials in children: approaches for improving performance. Expert Rev Clin Pharmacol. 2009;2:609\u201317.","journal-title":"Expert Rev Clin Pharmacol."},{"key":"733_CR20","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/clpt.2010.298","volume":"89","author":"P Zhao","year":"2011","unstructured":"Zhao P, Zhang L, Grillo JA, Liu Q, Bullock JM, Moon YJ, et al. Applications of physiologically based pharmacokinetic (PBPK) modeling and simulation during regulatory review. Clin Pharmacol Ther. 2011;89:259\u201367.","journal-title":"Clin Pharmacol Ther."},{"key":"733_CR21","doi-asserted-by":"crossref","first-page":"e150","DOI":"10.1038\/psp.2014.45","volume":"3","author":"AR Maharaj","year":"2014","unstructured":"Maharaj AR, Edginton AN. Physiologically based pharmacokinetic modeling and simulation in pediatric drug development. CPT Pharmacomet Syst Pharmacol. 2014;3:e150.","journal-title":"CPT Pharmacomet Syst Pharmacol."},{"key":"733_CR22","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1007\/s40262-017-0525-5","volume":"56","author":"CP Hornik","year":"2017","unstructured":"Hornik CP, Wu H, Edginton AN, Watt K, Cohen-Wolkowiez M, Gonzalez D. Development of a pediatric physiologically-based pharmacokinetic model of clindamycin using opportunistic pharmacokinetic data. Clin Pharmacokinet. 2017;56:1343\u201353.","journal-title":"Clin Pharmacokinet."},{"key":"733_CR23","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1208\/s12248-013-9451-0","volume":"15","author":"AR Maharaj","year":"2013","unstructured":"Maharaj AR, Barrett JS, Edginton AN. A workflow example of PBPK modeling to support pediatric research and development: case study with lorazepam. AAPS J. 2013;15:455\u201364.","journal-title":"AAPS J."},{"key":"733_CR24","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1038\/clpt.2012.19","volume":"91","author":"R Leong","year":"2012","unstructured":"Leong R, Vieira ML, Zhao P, Mulugeta Y, Lee CS, Huang SM, et al. Regulatory experience with physiologically based pharmacokinetic modeling for pediatric drug trials. Clin Pharmacol Ther. 2012;91:926\u201331.","journal-title":"Clin Pharmacol Ther."},{"key":"733_CR25","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.4155\/bio.15.38","volume":"7","author":"D Gonzalez","year":"2015","unstructured":"Gonzalez D, Melloni C, Poindexter BB, Yogev R, Atz AM, Sullivan JE, et al. Simultaneous determination of trimethoprim and sulfamethoxazole in dried plasma and urine spots. Bioanalysis. 2015;7:1137\u201349.","journal-title":"Bioanalysis."},{"key":"733_CR26","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1002\/jps.20502","volume":"95","author":"T Rodgers","year":"2006","unstructured":"Rodgers T, Rowland M. Physiologically based pharmacokinetic modelling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions. J Pharm Sci. 2006;95:1238\u201357.","journal-title":"J Pharm Sci."},{"key":"733_CR27","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1002\/jps.20323","volume":"94","author":"T Rodgers","year":"2005","unstructured":"Rodgers T, Leahy D, Rowland M. Tissue distribution of basic drugs: accounting for enantiomeric, compound and regional differences amongst beta-blocking drugs in rat. J Pharm Sci. 2005;94:1237\u201348.","journal-title":"J Pharm Sci."},{"key":"733_CR28","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1002\/jps.20322","volume":"94","author":"T Rodgers","year":"2005","unstructured":"Rodgers T, Leahy D, Rowland M. Physiologically based pharmacokinetic modeling 1: predicting the tissue distribution of moderate-to-strong bases. J Pharm Sci. 2005;94:1259\u201376.","journal-title":"J Pharm Sci."},{"key":"733_CR29","doi-asserted-by":"crossref","first-page":"3238","DOI":"10.1128\/AAC.45.11.3238-3241.2001","volume":"45","author":"E Ribera","year":"2001","unstructured":"Ribera E, Pou L, Fernandez-Sola A, Campos F, Lopez RM, Oca\u00f1a I, et al. Rifampin reduces concentrations of trimethoprim and sulfamethoxazole in serum in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother. 2001;45:3238\u201341.","journal-title":"Antimicrob Agents Chemother."},{"key":"733_CR30","first-page":"406","volume":"23","author":"A Cribb","year":"1995","unstructured":"Cribb A, Spielberg S, Griffin G. N4-hydroxylation of sulfamethoxazole by cytochrome P450 of the cytochrome P450C subfamily and reduction of sulfamethoxazole hydroxylamine in human and rat hepatic microsomes. Drug Metab Dispos. 1995;23:406\u201314.","journal-title":"Drug Metab Dispos."},{"key":"733_CR31","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1128\/AAC.05037-11","volume":"56","author":"H Kagaya","year":"2012","unstructured":"Kagaya H, Miura M, Niioka T, Saito M, Numakura K, Habuchi T, et al. Influence of NAT2 polymorphisms on sulfamethoxazole pharmacokinetics in renal transplant recipients. Antimicrob Agents Chemother. 2012;56:825\u20139.","journal-title":"Antimicrob Agents Chemother."},{"key":"733_CR32","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1097\/FPC.0000000000000058","volume":"24","author":"EM McDonagh","year":"2014","unstructured":"McDonagh EM, Boukouvala S, Aklillu E, Hein DW, Altman RB, Klein TE. PharmGKB summary: very important pharacogene information for N-acetyltransferase 2. Pharmacogenet Genom. 2014;24:409\u201325.","journal-title":"Pharmacogenet Genom."},{"key":"733_CR33","doi-asserted-by":"crossref","first-page":"D1074","DOI":"10.1093\/nar\/gkx1037","volume":"46","author":"DS Wishart","year":"2018","unstructured":"Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, et al. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018;46:D1074\u201382.","journal-title":"Nucleic Acids Res."},{"key":"733_CR34","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1128\/AAC.26.6.811","volume":"26","author":"MN Dudley","year":"1984","unstructured":"Dudley MN, Levitz RE, Quintiliani R, Hickingbotham JM, Nightingale CH. Pharmacokinetics of trimethoprim and sulfamethoxazole in serum and cerebrospinal fluid of adult patients with normal meninges. Antimicrob Agents Chemother. 1984;26:811\u20134.","journal-title":"Antimicrob Agents Chemother."},{"issue":"Suppl","key":"733_CR35","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1093\/infdis\/128.Supplement_3.S547","volume":"128","author":"SA Kaplan","year":"1973","unstructured":"Kaplan SA, Weinfeld RE, Abruzzo CW, McFaden K, Jack ML, Weissman L. Pharmacokinetic profile of trimethoprim-sulfamethoxazole in man. J Infect Dis. 1973;128(Suppl):547\u201355.","journal-title":"J Infect Dis."},{"key":"733_CR36","first-page":"505","volume":"5","author":"JR Medina","year":"2013","unstructured":"Medina JR, Miranda M, Hurtado M, Dominguez-Ramirez AM, Ruiz-Segura JC. Simultaneous determination of trimethoprim and sulfamethoxazole in immediate-release oral dosage forms by first-order derivative spectroscopy: application to dissolution studies. Int J Pharm Pharm Sci. 2013;5:505\u201310.","journal-title":"Int J Pharm Pharm Sci."},{"key":"733_CR37","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ejps.2010.05.014","volume":"41","author":"P Paixao","year":"2010","unstructured":"Paixao P, Gouveia L, Morais J. Prediction of the in vitro permeability determined in Caco-2 cells by using artificial neural networks. Eur J Pharm Sci. 2010;41:107\u201317.","journal-title":"Eur J Pharm Sci."},{"key":"733_CR38","doi-asserted-by":"crossref","first-page":"E3","DOI":"10.1208\/ps020103","volume":"2","author":"WL Hayton","year":"2000","unstructured":"Hayton WL. Maturation and growth of renal function: dosing renally cleared drugs in children. AAPS PharmSci. 2000;2:E3.","journal-title":"AAPS PharmSci."},{"key":"733_CR39","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1124\/dmd.114.058834","volume":"42","author":"B Achour","year":"2014","unstructured":"Achour B, Barber J, Rostami-Hodjegan A. Expression of hepatic drug-metabolizing cytochrome p450 enzymes and their intercorrelations: a meta-analysis. Drug Metab Dispos. 2014;42:1349\u201356.","journal-title":"Drug Metab Dispos."},{"key":"733_CR40","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1097\/00008571-199308000-00006","volume":"3","author":"W Weber","year":"1993","unstructured":"Weber W, Vatsis K. Individual variability in p-aminobenzoic acid N-acetylation by human N-acetyltransferase (NAT1) of peripheral blood. Pharmacogenetics. 1993;3:209\u201312.","journal-title":"Pharmacogenetics."},{"key":"733_CR41","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.2165\/00003088-200645100-00005","volume":"45","author":"AN Edginton","year":"2006","unstructured":"Edginton AN, Schmitt W, Willmann S. Development and evaluation of a generic physiologically based pharmacokinetic model for children. Clin Pharmacokinet. 2006;45:1013\u201334.","journal-title":"Clin Pharmacokinet."},{"key":"733_CR42","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s10928-007-9053-5","volume":"34","author":"S Willmann","year":"2007","unstructured":"Willmann S, H\u00f6hn K, Edginton A, Sevestre M, Solodenko J, Weiss W, et al. Development of a physiologically-based whole-body population model for assessing the influence of individual variability on the pharmacokinetics of drugs. J Pharmacokinet Pharmacodyn. 2007;34:401\u201331.","journal-title":"J Pharmacokinet Pharmacodyn."},{"key":"733_CR43","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1080\/00387010.2012.657332","volume":"46","author":"F Deng","year":"2013","unstructured":"Deng F, Dong C, Liu Y, Yu Y. Study on the interaction between trimethoprim and human serum albumin by spectroscopic and molecular modeling methods. Spectrosc Lett. 2013;46:13\u201320.","journal-title":"Spectrosc Lett."},{"key":"733_CR44","doi-asserted-by":"crossref","first-page":"683","DOI":"10.2165\/00003088-200645070-00004","volume":"45","author":"AN Edginton","year":"2006","unstructured":"Edginton AN, Schmitt W, Voith B, Willmann S. A mechanistic approach for the scaling of clearance in children. Clin Pharmacokinet. 2006;45:683\u2013704.","journal-title":"Clin Pharmacokinet."},{"key":"733_CR45","doi-asserted-by":"crossref","unstructured":"Willmann S, Lippet J, Sevestre M, Solodenko, Fois F, Schmitt W. PK-Sim\u00ae: a physiologically based pharmacokinetic \u2018whole-body\u2019 model. Biosilico. 2003;1:121-4.","DOI":"10.1016\/S1478-5382(03)02342-4"},{"key":"733_CR46","doi-asserted-by":"crossref","first-page":"e01813","DOI":"10.1128\/AAC.01813-17","volume":"62","author":"J Autmizguine","year":"2018","unstructured":"Autmizguine J, Melloni C, Hornik CP, Dallefeld S, Harper B, Yogev R, et al. Population pharmacokinetics of trimethoprim-sulfamethoxazole in infants and children. Antimicrob Agents Chemother. 2018;62:e01813\u20137.","journal-title":"Antimicrob Agents Chemother."},{"key":"733_CR47","unstructured":"ACS Demographic and Housing Estimates\u20142011\u20132015 American Community Survey 5-year estimates. U.S. Census Bureau. https:\/\/factfinder.census.gov\/faces\/tableservices\/jsf\/pages\/productview.xhtml. Accessed 5 Sept 2018."},{"key":"733_CR48","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/j.1552-4604.1974.tb02300.x","volume":"14","author":"P Kremers","year":"1974","unstructured":"Kremers P, Duvivier J, Heusghem C. Pharmacokinetic studies of co-trimoxazole in man after single and repeated doses. J Clin Pharmacol. 1974;14:112\u20137.","journal-title":"J Clin Pharmacol."},{"key":"733_CR49","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.1128\/AAC.00206-07","volume":"51","author":"MJ Cenizal","year":"2007","unstructured":"Cenizal MJ, Skiest D, Luber S, Bedimo R, Davis P, Fox P, et al. Prospective randomized trial of empiric therapy with trimethoprim-sulfamethoxazole or doxycycline for outpatient skin and soft tissue infections in an area of high prevalence of methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2007;51:2628\u201330.","journal-title":"Antimicrob Agents Chemother."},{"key":"733_CR50","doi-asserted-by":"crossref","first-page":"2704","DOI":"10.1128\/AAC.00301-10","volume":"54","author":"RE Mendes","year":"2010","unstructured":"Mendes RE, Moet GJ, Janechek MJ, Jones RN. In vitro activity of telavancin against a contemporary worldwide collection of Staphylococcus aureus isolates. Antimicrob Agents Chemother. 2010;54:2704\u20136.","journal-title":"Antimicrob Agents Chemother."},{"key":"733_CR51","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1128\/AAC.00274-13","volume":"57","author":"KS Thomson","year":"2013","unstructured":"Thomson KS, Goering RV. Activity of tedizolid (TR-700) against well-characterized methicillin-resistant Staphylococcus aureus straings of diverse epidemiological origins. Antimicrob Agents Chemother. 2013;57:2892\u20135.","journal-title":"Antimicrob Agents Chemother."},{"key":"733_CR52","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/0732-8893(95)00053-D","volume":"22","author":"WA Craig","year":"1995","unstructured":"Craig WA. Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins. Diagn Microbiol Infect Dis. 1995;22:89\u201396.","journal-title":"Diagn Microbiol Infect Dis."},{"key":"733_CR53","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1093\/clinids\/4.2.566","volume":"4","author":"GR Siber","year":"1982","unstructured":"Siber GR, Gorham CC, Ericson JF, Smith AL. Pharmacokinetics of intravenous trimethoprim-sulfamethoxazole in children and adults with normal and impaired renal function. Rev Infect Dis. 1982;4:566\u201378.","journal-title":"Rev Infect Dis."},{"key":"733_CR54","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1056\/NEJMra035092","volume":"349","author":"GL Kearns","year":"2003","unstructured":"Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE. Developmental pharmacology\u2014drug disposition, action, and therapy in infants and children. N Engl J Med. 2003;349:1157\u201367.","journal-title":"N Engl J Med."},{"key":"733_CR55","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1093\/cid\/cir034","volume":"52","author":"C Liu","year":"2011","unstructured":"Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. Clin Infect Dis. 2011;52:285\u201392.","journal-title":"Clin Infect Dis."},{"key":"733_CR56","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1080\/00498250400021796","volume":"35","author":"S Yamaori","year":"2005","unstructured":"Yamaori S, Yamazaki H, Iwano S, Kiyotani K, Matsumura K, Saito T, et al. Ethnic differences between Japanese and Caucasians in the expression levels of mRNAs for CYP3A4, CYP3A5, and CYP3A7: lack of co-regulation of the expression of CYP3A in Japanese livers. Xenobiotica. 2005;35:69\u201383.","journal-title":"Xenobiotica."},{"key":"733_CR57","unstructured":"Benjamin D. Pharmacokinetics of understudied drugs administered to children per standard of care (PTN_POPS) [ClinicalTrials.gov identifier NCT01431326]. US National Institutes of Health, ClinicalTrials.gov. https:\/\/clinicaltrials.gov. Accessed 23 Dec 2018"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-018-00733-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40262-018-00733-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-018-00733-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,13]],"date-time":"2022-09-13T01:38:36Z","timestamp":1663033116000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40262-018-00733-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,6]]},"references-count":57,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019,7,1]]}},"alternative-id":["733"],"URL":"https:\/\/doi.org\/10.1007\/s40262-018-00733-1","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,6]]},"assertion":[{"value":"6 March 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"This work was funded by the National Institutes of Health (1R01-HD076676-01A1; M.C.W.). Funding acknowledgements: NIGMS\/NICHD (National Institute of General Medical Sciences\/National Institute of Child Health and Human Development) 2T32GM086330-06; Clinical and Translational Science Awards (CTSA).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Stephen J. Balevic receives salary and research support from the National Institutes of Health (5R01-HD076676-04, HHSN275201000003I, the Rheumatology Research Foundation\u2019s Scientist Development Award, and the Thrasher Research Fund. Andrea N. Edginton receives support for research from the National Institutes of Health (1R01-HD076676-01A1 [PI: Cohen-Wolkowiez]). Elizabeth J. Thompson, Huali Wu, Anil Maharaj, Marjan Cobbaert, Anthony P. Cunningham, Christoph P. Hornik, and Michael Cohen-Wolkowiez have nothing to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}